Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al.
Record ID 32010000393
Authors' objectives: The overall aim is to evaluate the effectiveness, cost-effectiveness and acceptability of treatments for men with localised prostate cancer within the context of a pragmatic randomised controlled trial. This will compare 3 treatments (active monitoring, radical prostatectomy and radical radiotherapy). Specific objectives are as follows: 1) To assess survival at 5, 10 years and 15 years following treatment 2) To investigate a number of short and medium-term outcomes, including: disease progression (biochemical and clinical), treatment complications, lower urinary tract symptoms, psychosocial impact of case-finding and treatment, including generic health status, quality of life and sexual function 3) To estimate the resource use and costs of case-finding, treatment and follow-up, and to compare costs and outcomes of treatment in terms of survival and health related quality of life. 4) To collect material suitable for basic science research, and develop a network for collaborative research.
Project Status: Completed
Year Published: 2020
Requestor: NIHR Health Technology Assessment programme
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: England
MeSH Terms
  • Prostatic Neoplasms
  • Prostatectomy
  • Radiotherapy
  • Watchful Waiting
  • Disease-Free Survival
  • Prostate-Specific Antigen
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
Contact Email:

2010 Queen's Printer and Controller of HMSO

This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.